TOP TEN perturbations for 39319_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39319_at
Selected probe(set): 205270_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39319_at (205270_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):-4.147084Number of Samples:2 / 2
| Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
| Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
EBNA2 overexpr. study 1 (24h) / EBNA2 overexpr. study 1 (4h)
Relative Expression (log2-ratio):-3.8194027Number of Samples:3 / 3
| Experimental | EBNA2 overexpr. study 1 (24h) |
| EREB2-5 cell line stably transfected with the chimeric Epstein-Barr virus-encoded nuclear antigen 2 (EBNA2) and control expression plasmid coding for bacterial chloramphenicol acetyltransferase (CAT) gene and . CAT was used as a negative control. Briefly, before the CAT and EBNA2 induction, cells were maintained in RPMI media and deprived of estrogen for 3 days before doxycycline and estrogen was added. Expression of EBNA2 was induced after addition of estrogen and expression of CAT was induced by the addition of doxycycline to a final concentration of 100 ng/mL medium. Doxycycline induced cells were harvested 24 hours after induction. Because EBNA2 is essential for the proliferation of EBV-infected cells, EREB2-5 cells grow only in the presence of estrogen. Before the preparation of RNA, NGFR cells were purified by MACS separation to enrich the cells with a transcriptional response to doxycycline. | |
| Control | EBNA2 overexpr. study 1 (4h) |
| EREB2-5 cell line stably transfected with the chimeric Epstein-Barr virus-encoded nuclear antigen 2 (EBNA2) and control expression plasmid coding for bacterial chloramphenicol acetyltransferase (CAT) gene and . CAT was used as a negative control. Briefly, before the CAT and EBNA2 induction, cells were maintained in RPMI media and deprived of estrogen for 3 days before doxycycline and estrogen was added. Expression of EBNA2 was induced after addition of estrogen and expression of CAT was induced by the addition of doxycycline to a final concentration of 100 ng/mL medium. Doxycycline induced cells were harvested 4 hours after induction. Because EBNA2 is essential for the proliferation of EBV-infected cells, EREB2-5 cells grow only in the presence of estrogen. Before the preparation of RNA, NGFR cells were purified by MACS separation to enrich the cells with a transcriptional response to doxycycline. |
Crohn's disease study 10 / colorectal cancer study 13 (tvvad)
Relative Expression (log2-ratio):3.5764666Number of Samples:4 / 3
| Experimental | Crohn's disease study 10 |
| Colon biopsies derived from patients with Crohn's disease. | |
| Control | colorectal cancer study 13 (tvvad) |
| Colon biopsies derived from patients with low grade tubulovillous/villous adenoma. |
cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue
Relative Expression (log2-ratio):3.4077091Number of Samples:4 / 8
| Experimental | cutaneous T-cell lymphoma study 1 (tumor phase) |
| Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal). | |
| Control | normal skin tissue |
| Skin biopsies from healthy individuals. |
expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):-3.3798323Number of Samples:2 / 2
| Experimental | expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary. | |
| Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
collecting duct carcinoma study 1 / normal kidney tissue (fetal)
Relative Expression (log2-ratio):3.283742Number of Samples:2 / 2
| Experimental | collecting duct carcinoma study 1 |
| Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC). | |
| Control | normal kidney tissue (fetal) |
| Normal fetal kidney tissue samples. |
PMA study 3 (shRNA contr.) / mock treated / transduced Jurkat cell sample
Relative Expression (log2-ratio):3.2494907Number of Samples:2 / 2
| Experimental | PMA study 3 (shRNA contr.) |
| Jurkat cells were transduced with a control shRNA and then treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:--- | |
| Control | mock treated / transduced Jurkat cell sample |
| Jurkat cells were transduced with a control shRNA and then mock treated. |
renal cell carcinoma study 4 / normal kidney tissue (fetal)
Relative Expression (log2-ratio):3.2072172Number of Samples:26 / 2
| Experimental | renal cell carcinoma study 4 |
| Tumor tissue samples from the kidney of patients with renal cell carcinoma (RCC). | |
| Control | normal kidney tissue (fetal) |
| Normal fetal kidney tissue samples. |
glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):3.129942Number of Samples:2 / 3
| Experimental | glioma study 17 (anaplastic astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):-3.111578Number of Samples:8 / 2
| Experimental | expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary. | |
| Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |